Printer Friendly

Aurigene doses first volunteer under Phase 1 INDUS trial of AUR-101.

M2 PHARMA-July 12, 2018-Aurigene doses first volunteer under Phase 1 INDUS trial of AUR-101

(C)2018 M2 COMMUNICATIONS

Biotechnology company Aurigene reported on Wednesday the start of dosing of healthy volunteers with AUR-101 under its Phase 1 INDUS trial for the treatment of IL17-driven immunological conditions, including psoriasis.

AUR-101 is a selective, potent inverse agonist of the receptor RoR?t, designed as an oral agent for the treatment of IL17-driven immunological conditions, including psoriasis. AUR-101, with a good ADME/PK profile and high bioavailability, has demonstrated inhibition of IL-17A in whole blood from psoriasis patients and also very significant reduction in ear swelling and histopathology scores in two separate pre-clinical psoriasis models.

The company added the study is designed to evaluate the safety signals, pharmacodynamic modulation and recommended dosage for Phase 2 studies (RP2D).

According to the company, it expects the data from the INDUS study to be available by December 2018.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2018 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Geographic Code:8MARS
Date:Jul 12, 2018
Words:163
Previous Article:RedDress passes US FDA's 510(k) clearance for RD1 system for wound management.
Next Article:AcelRx Pharmaceuticals proposes public offering of common stock.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters